Retinopathy of prematurity in ethiopia: a prospective multicenter study on prevalence, risk factors, and treatment outcomes
Year: 2026
Type: article
Abstract: Retinopathy of prematurity (ROP) is an increasing cause of childhood blindness in Africa due to absent or underdeveloped screening and treatment programs. In Ethiopia, only a few centers provide continuous screening and treatment for preterm infants with ROP, and data on its incidence and treatment outcomes remain limited. This multicenter study aimed to determine the prevalence, risk factors, and treatment outcomes of ROP in two tertiary eye care centers in Ethiopia. A prospective longitudinal study was conducted in two university hospitals with level-three neonatal intensive care units (NICUs). All preterm infants with gestational age ≤ 34 weeks, birth weight ≤ 2000 g, or an unstable clinical course were included. Demographic, neonatal, and treatment data were collected and analyzed using SPSS version 26. A total of 173 preterm infants (346 eyes) were examined. The cohort showed a slight female predominance, with a male-to-female ratio of 0.83. Mean birth weight was 1299.6 g (range: 700–3400 g), and mean gestational age was 31.3 weeks (range: 27–40 weeks). ROP of any stage was diagnosed in 80 eyes (23.1%). The disease was bilateral in 35 infants (77.8%) and unilateral in 10 (22.2%). Stage 1 (35 eyes, 43.75%) was the most common presentation, followed by stage 2 (29 eyes, 36.25%), and Stage 3 (8 eyes, 10%). Aggressive posterior ROP (APROP) was diagnosed in 8 eyes (10%). Overall, type 1 ROP requiring treatment was seen in 15 eyes (18.75%). On multivariable logistic regression analysis, blood transfusion (AOR=2.71, p=0.028), multiple birth (AOR=4.29, p<0.001), intraventricular hemorrhage (IVH) (AOR=7.82, p<0.001), premature rupture of membranes (PROM) (AOR= 3.94, p=0.022), maternal hypertension(AOR=3.02, p=0.035), lower birth weight (AOR=2.67,p=0.004), lower gestational age (AOR=1.94,p=0.043) and study center (AOR = 5.08, p = 0.001) were independently associated with ROP. The majority of ROP cases (81.25%) were managed by observation, while 15.0% were treated with intravitreal bevacizumab alone and 3.75% underwent bevacizumab treatment followed by peripheral retinal laser ablation. Overall, 81.25% regressed spontaneously, 16.25% regressed after treatment, and 2.5% progressed to retinal detachment. The prevalence of ROP was lower than previously reported national data. However, a higher prevalence of APROP was observed, a finding not reported in earlier studies. In multivariable analysis, lower gestational age, lower birth weight, blood transfusion, multiple birth, IVH, PROM, maternal hypertension, and study center were independently associated with ROP.
Source: BMC Ophthalmology
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,990
OpenAlex ID: W7237367121
FWCI:
Cites:
Cited by:
Related to:
